Tagged with ISS

Switzerland Swiss Biotech’s Michael Altorfer explains how Switzerland’s biotech industry continues to grow, driven by startups and SMEs and supported by strong international collaborations across the entire value chain. He outlines how Swissmedic’s proactive approach to advanced therapies and participation in the Access Consortium enables faster and more efficient drug approval…

Switzerland Switzerland’s healthcare system is at a crossroads. Although still one of the world’s bastions of biopharmaceutical innovation, the country’s domestic healthcare environment is under increasing pressure from rising costs, mounting drug shortages, and a regulatory environment that is slow to adapt. What role could pharmacies and the off-patent industry play…

Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…

Switzerland Martine Ruggli discusses the evolving role of pharmacists in Switzerland’s healthcare system, addressing challenges and opportunities in digitalization, drug shortages, and regulatory reforms, as well as the need to leverage pharmacists’ expertise more broadly.   Investing in and empowering pharmacists is essential for improving the quality, accessibility, and efficiency of…

Mexico The Swiss Chamber in Mexico (SwissCham) represents Swiss companies operating in Mexico, a country that has become Switzerland’s top commercial partner in Latin America. Executive Director Emilia Pfeiffer outlines the role of SwissCham, the robust presence of the Swiss healthcare and life sciences companies in the country, the Chamber’s advocacy…

Switzerland While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience with the record revenues of…

Switzerland For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World Health Organisation (WHO), Swissmedic also saw a Good Manufacturing Practice (GMP) agreement between Switzerland and the US FDA come into…

China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre.   COVID global emergency over but risks remain, says China health official (Reuters)…

Europe As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by reducing regulatory exclusivity, speeding up review processes and reinforcing supply chains…

Europe Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the general pharmaceutical legislation and why it would prove unsustainable for smaller companies and…

Europe Pierre Meulien, Executive Director- Innovative Health Initiative, presents the public-private joint undertaking that boasts a total budget of EUR 2.4 billion and aims to build on the work of the Innovative Medicines Initiative to boost collaboration between the European pharmaceutical and related industries and the European Commission.   The Innovative…

Europe Sparks, the Swiss Exchange’s newly launched small and medium sized enterprise (SME) trading venue, intends to make it easier for biotech SMEs to raise capital and strengthen their profile. The Swiss biotech sector has proven to be attractive for investors, with venture capital investments rising almost steadily over the past…